Cargando…

Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine

The mainstay of treatment for opioid use disorder are medications, methadone (a full opioid agonist), or buprenorphine (a partial opioid agonist), in conjunction with psychosocial interventions. Both treatments are effective but safety, efficacy, and patient preference can lead to a decision to chan...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Duncan, Hayes, Victoria, Demirkol, Apo, Lintzeris, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919996/
https://www.ncbi.nlm.nih.gov/pubmed/33870954
http://dx.doi.org/10.1097/ADM.0000000000000854
_version_ 1784669034523918336
author Hill, Duncan
Hayes, Victoria
Demirkol, Apo
Lintzeris, Nicholas
author_facet Hill, Duncan
Hayes, Victoria
Demirkol, Apo
Lintzeris, Nicholas
author_sort Hill, Duncan
collection PubMed
description The mainstay of treatment for opioid use disorder are medications, methadone (a full opioid agonist), or buprenorphine (a partial opioid agonist), in conjunction with psychosocial interventions. Both treatments are effective but safety, efficacy, and patient preference can lead to a decision to change from one treatment to the other. Transfer from buprenorphine to methadone is not clinically challenging; however, changing from methadone to buprenorphine is more complex. Published reports describe varied approaches to manage this transfer to both minimize patient symptoms associated with withdrawal from methadone and reduce risk of precipitating withdrawal symptoms with introduction of the partial agonist buprenorphine [Lintzeris et al. J Addict Med. 2020; in press]. There is no single approach for methadone to buprenorphine that is superior to others and no approach that is suitable for all case presentations. This case conference describes three different approaches to achieve a successful methadone to buprenorphine transfer and provides commentary on how the case may be managed based on published transfer “strategies.”
format Online
Article
Text
id pubmed-8919996
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-89199962022-03-18 Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine Hill, Duncan Hayes, Victoria Demirkol, Apo Lintzeris, Nicholas J Addict Med Reviews The mainstay of treatment for opioid use disorder are medications, methadone (a full opioid agonist), or buprenorphine (a partial opioid agonist), in conjunction with psychosocial interventions. Both treatments are effective but safety, efficacy, and patient preference can lead to a decision to change from one treatment to the other. Transfer from buprenorphine to methadone is not clinically challenging; however, changing from methadone to buprenorphine is more complex. Published reports describe varied approaches to manage this transfer to both minimize patient symptoms associated with withdrawal from methadone and reduce risk of precipitating withdrawal symptoms with introduction of the partial agonist buprenorphine [Lintzeris et al. J Addict Med. 2020; in press]. There is no single approach for methadone to buprenorphine that is superior to others and no approach that is suitable for all case presentations. This case conference describes three different approaches to achieve a successful methadone to buprenorphine transfer and provides commentary on how the case may be managed based on published transfer “strategies.” Lippincott Williams & Wilkins 2022 2021-04-15 /pmc/articles/PMC8919996/ /pubmed/33870954 http://dx.doi.org/10.1097/ADM.0000000000000854 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Reviews
Hill, Duncan
Hayes, Victoria
Demirkol, Apo
Lintzeris, Nicholas
Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine
title Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine
title_full Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine
title_fullStr Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine
title_full_unstemmed Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine
title_short Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine
title_sort clinical case conference: strategies for transferring from methadone to buprenorphine
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919996/
https://www.ncbi.nlm.nih.gov/pubmed/33870954
http://dx.doi.org/10.1097/ADM.0000000000000854
work_keys_str_mv AT hillduncan clinicalcaseconferencestrategiesfortransferringfrommethadonetobuprenorphine
AT hayesvictoria clinicalcaseconferencestrategiesfortransferringfrommethadonetobuprenorphine
AT demirkolapo clinicalcaseconferencestrategiesfortransferringfrommethadonetobuprenorphine
AT lintzerisnicholas clinicalcaseconferencestrategiesfortransferringfrommethadonetobuprenorphine